MIRA

MIRA Pharmaceuticals, Inc. (MIRA) Scenario Analysis Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Overall Score

Base Case

MIRA remains a micro-cap with a very small enterprise value (~$32.1M) and no revenue or operating profit in the TTM period.

Liquidity is extremely strong on paper with a current ratio of 200.1x and cash ratio of 88.4x, but this is offset by continued negative operating and free cash flow.

Profitability remains deeply negative, with ROA of -1.16%, ROE of -1.07%, and ROIC of -1.15% in the TTM period.

Valuation is not supported by earnings or cash flow, as TTM earnings yield is -0.27% and free cash flow yield is -0.13%.

Upside Case

A turnaround would require the company to convert its large liquidity cushion into sustained revenue generation and positive operating cash flow.

The balance sheet provides some near-term flexibility, but there is no evidence in the current TTM metrics of improving margins or operating leverage.

If management can establish a viable operating model, the low absolute enterprise value could allow for outsized percentage upside from a small revenue base.

Downside Case

The main risk is continued cash burn without meaningful revenue, which would eventually erode the current liquidity cushion.

Negative profitability and negative cash flow metrics suggest the business remains highly speculative and dependent on future financing or operational improvement.

With no recent news catalyst, there is no evidence of a near-term inflection to offset the weak fundamentals.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MIRA Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →